Incyte (INCY) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.57% |
| Dec 31, 2025 | 14.63% |
| Sep 30, 2025 | 14.24% |
| Jun 30, 2025 | 12.21% |
| Mar 31, 2025 | 13.61% |
| Dec 31, 2024 | 5.82% |
| Sep 30, 2024 | 5.53% |
| Jun 30, 2024 | 5.93% |
| Mar 31, 2024 | 20.93% |
| Dec 31, 2023 | 21.93% |
| Sep 30, 2023 | 22.29% |
| Jun 30, 2023 | 22.30% |
| Mar 31, 2023 | 22.34% |
| Dec 31, 2022 | 21.79% |
| Sep 30, 2022 | 19.18% |
| Jun 30, 2022 | 31.81% |
| Mar 31, 2022 | 31.95% |
| Dec 31, 2021 | 55.14% |
| Sep 30, 2021 | 53.46% |
| Jun 30, 2021 | 58.12% |
| Mar 31, 2021 | 64.31% |
| Dec 31, 2020 | 72.46% |
| Sep 30, 2020 | 93.24% |
| Jun 30, 2020 | 111.67% |
| Mar 31, 2020 | 117.60% |
| Dec 31, 2019 | 102.24% |
| Sep 30, 2019 | 96.15% |
| Jun 30, 2019 | 72.20% |
| Mar 31, 2019 | 71.51% |
| Dec 31, 2018 | 64.30% |
| Sep 30, 2018 | 128.74% |
| Jun 30, 2018 | 130.00% |
| Mar 31, 2018 | 64.25% |
| Dec 31, 2017 | 62.47% |
| Sep 30, 2017 | 58.46% |
| Jun 30, 2017 | 46.41% |
| Mar 31, 2017 | 42.53% |
| Dec 31, 2016 | 30.93% |
| Sep 30, 2016 | 32.24% |
| Jun 30, 2016 | 33.12% |
| Mar 31, 2016 | 33.18% |
| Dec 31, 2015 | 31.49% |